• Media type: E-Article
  • Title: Cowpea Mosaic Virus Nanoparticle Enhancement of Hypofractionated Radiation in a B16 Murine Melanoma Model
  • Contributor: Duval, Kayla E. A.; Wagner, Robert J.; Beiss, Veronique; Fiering, Steven N.; Steinmetz, Nicole F.; Hoopes, P. Jack
  • imprint: Frontiers Media SA, 2020
  • Published in: Frontiers in Oncology
  • Language: Not determined
  • DOI: 10.3389/fonc.2020.594614
  • ISSN: 2234-943X
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Introduction</jats:title><jats:p>Virus and virus-like nanoparticles (VNPs) have been used for a variety of preclinical treatments, including <jats:italic>in situ</jats:italic> anti-cancer vaccination. The Cowpea mosaic virus (CPMV) is a VNP that has shown the ability to stimulate an anti-cancer immune response. The hypothesis of this study is two-fold: that intratumoral CPMV enhances the immunogenetic and cytotoxic response of hypofractionated radiation (15 Gy or 3 x 8 Gy), and that the effect differs between fraction regimens in the murine B16 flank melanoma model.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>CPMV nanoparticles were delivered intratumorally, 100 μg/tumor to B16 murine melanoma flank tumors alone, and in combination with either 15 Gy or 3 x 8 Gy (3 consecutive days). Tumors were assessed for immune and cytotoxic gene and protein expression, and cytotoxic T cell infiltration 4 days post treatment. Treatment based tumor control was assessed by a 3-fold tumor growth assay.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Both CPMV and radiation alone demonstrated the activation of a number of important immune and cytotoxic genes including natural killer cell and T cell mediated cytotoxicity pathways. However, the combination treatment activated greater expression than either treatment alone. CPMV combined with a single dose of 15 Gy demonstrated greater immune and cytotoxic gene expression, protein expression, CD8+ T cell infiltration activity, and greater tumor growth delay compared to 3 x 8 Gy with CPMV.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>CPMV presents a unique and promising hypofractionated radiation adjuvant that leads to increased anti-tumor cytotoxic and immune signaling, especially with respect to the immune mediated cytotoxicity, immune signaling, and toll-like receptor signaling pathways. This improvement was greater with a single dose than with a fractionated dose.</jats:p></jats:sec>
  • Access State: Open Access